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evaluations is typically not long lasting. We investigated the
major factors affecting the “expiration date” of economic evalu-
ations using conjugate meningococcal vaccination strategies as
case example. METHODS: In March 2007, we conducted a
systematic literature review of journal articles, based on a
comprehensive key-word based search in generic (PUBMED,
EMBASE) and specialized electronic databases (HEED, NHS
EED), accompanied by manual searches of speciﬁc journals. The
applied methodology in the identiﬁed studies was compared
and matched to the respective national guidelines for economic
evaluation. The current external validity of the study results
and possible adjustments for its improvement were examined.
RESULTS: A total of six published economic evaluations of
conjugate meningococcal vaccination strategies were found.
Overall, they showed that the investigated vaccination strategies
were cost-effective, especially the ones targeting children at
approximately age 1. Adherence of the evaluations to the respec-
tive guidelines was high except for the discount rate. The latter
was however directly related to the recent change in Dutch and
UK recommendations. Sensitivity analysis was available for
many factors, inclusive the discount rate allowing the estimation
of the impact of those recent changes. Similarly, the effect of new
ﬁndings about the vaccination protection duration and herd
immunity could also be estimated for those evaluations that
included those factors in their sensitivity analysis. These were
however scarce. CONCLUSION: An extensive sensitivity analy-
sis for all important factors that might change over time can
extend the expiration date of economic evaluations. Ultimately,
user-friendly and highly ﬂexible models available on the internet
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OBJECTIVES: The purpose of this study was to validate cross-
sectionally the MINI-HIV questionnaire in HIV patients treated
with saquinavir in Spanish hospitals. METHODS: Cross-
sectional observational post-launch and multicentre study. HIV
Patients over 18 years, who were under HAART with Saquinavir.
One visit was carried out. Socio-demographic and clinical vari-
ables (symptoms, time since HIV diagnosis, CDC stage, CD4 and
viral load), treatment adherence (GEEMA questionnaire), a ques-
tion about general health status and the speciﬁc QoL question-
naire Mini-HIV (0 = better QoL; 100 = worse Qol) were
collected. RESULTS: A total of 948 patients were included.
Mean age (SD) was 42 (8.62) years. Mean (SD) time since diag-
nosis was 11.3 (5.6). A total of 36.1% were in Stage C of CDC.
Mean score (SD) obtained in Mini-HIV was of 30.2 (17.8). A
total of 64.9% had bad Qol (cut of point under 22 score).
Correlation between Mini-HIV score and CD4 was low (-0.134)
although it was signiﬁcant (p < 0.01). In patients with detectable
viral load mean (SD) of MINI-HIV score was lower than in
patients with undetectable viral load (32.9 (18.1) vs. 28.8 (17.5);
p < 0.01). QoL was worse in patients who presented symptoms
in the last two weeks or that presented other concomitant disease
(p < 0.01). The more frequent symptoms were weakness, anxiety,
insomnia and depression. There was no difference in MINI-HIV
score according to the form of administration (BID vs OD).
Internal consistency of MINI-HIV was of 0.914 (higher than 0.7
theoretical). General health status was ‘very good’ in 42.3% of
the patients. MINI-HIV scores were related to the general health
status question (p < 0.01). Non adherent patients obtained
higher scores (worse Qol) than adherent patients (p < 0.01).
CONCLUSION: The results of this study show that Mini-HIV
has good psychometrical properties and can be a good tool for
monitoring treatment effectiveness and health states of HIV
patients.
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OBJECTIVES: To develop and validate a self-administered ques-
tionnaire assessing subjects’ perception and experience with
injection, and their acceptance of injection site reactions (ISR)
including pain following inﬂuenza vaccination. METHODS: Fol-
lowing a literature review, the VAPI questionnaire was simulta-
neously developed in US English, German and French, based on
interviews of subjects (n = 33) vaccinated intramuscularly (IM)
or intradermally (ID) with an inﬂuenza vaccine. Items were
generated from subjects’ verbatim, comprehension tested with
elderly and adult vaccinees (n = 23); then a linguistic validation
was done. The initial, 44 item-version of the questionnaire was
administered 21 days after vaccination to subjects from Belgium,
France, Spain, the UK, Germany and Italy who were participat-
ing in clinical trials comparing ID versus IM inﬂuenza vaccina-
tion.Scale construction and item reduction were conducted using
principal component and multitrait analyses with 549 English
subjects. Psychometric validation of the ﬁnal questionnaire was
performed per country (n = 5,543) and included: 1) construct
validity by item convergent and discriminant validity, 2) internal
consistency reliability by Cronbach’s alpha and 3) clinical valid-
ity by describing the scores according to ISR severity. RESULTS:
After item reduction, the ﬁnal questionnaire comprised 4 multi-
item dimensions (“bother”; “arm movement”; “sleep”; “accept-
ability”) grouping 16 items plus 5 individual items (anxiety
before vaccination; bother by pain during vaccination; satisfac-
tion with the injection system; anxiety of being vaccinated next
year; willingness to be vaccinated again). Item convergent and
discriminant validity was conﬁrmed for all scales in most coun-
tries. Multi-item dimension internal consistency reliability was
good to excellent for all countries (Cronbach’s alpha ranging
from 0.73 to 0.94), except for the “sleep” dimension in Italy
(0.68). Dimension scores demonstrated good clinical validity:
greater severity of ISR was associated with higher scores. CON-
CLUSION: The self-administered VAPI questionnaire is valid
and reliable. Therefore, it is a promising tool for the assessment
of the acceptance of a vaccine injection system.
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OBJECTIVES: Compare data from a large national EMR in the
US to national published data. METHODS: Data from GE
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